Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Dec 6:11:1445031.
doi: 10.3389/fmed.2024.1445031. eCollection 2024.

The evaluation of prothrombin time and activated partial thromboplastin time among diabetic and healthy controls in Africa: systematic review and meta-analysis

Fasil Getu  1 , Ermiyas Alemayehu  2 , Addisu Tesfaye  1 , Birhanu Genanew  3 , Muluken Walle  1
Affiliations

The evaluation of prothrombin time and activated partial thromboplastin time among diabetic and healthy controls in Africa: systematic review and meta-analysis

Fasil Getu et al. Front Med (Lausanne). .

Abstract

Introduction: Diabetes Mellitus (DM) is a disorder of multiple etiologies characterized by chronic hyperglycemia resulting from defects in insulin secretion and/or insulin action. DM patients have a disturbance of hemostasis, leading to a prothrombotic state characterized by platelet hypersensitivity, coagulation factor disorders, and hypo-fibrinolysis. Therefore, the primary goal of this systematic review and meta-analysis was to determine the pooled Standard Mean Difference (SMD) of prothrombin time (PT) and activated partial thromboplastin time (APTT) of DM patients in Africa.

Methods: This systematic review and meta-analysis was conducted based on the guidelines of the PRISMA. PubMed, Google Scholar, Science Direct, Dove Press, Cochrane Online, and African journals online were searched systematically. The qualities of the included studies were assessed by two independent reviewers using the JBI critical appraisal tools. Data were extracted in an Excel sheet and then exported to STATA version 11 for analysis. A Random-effect model was fitted to estimate the pooled SMD and Higgins I-square test statistics were done to test the heterogeneity of studies. Funnel plots analysis and Egger-weighted regression tests were done to detect publication bias.

Results: The pooled SMD of PT among DM patients in Africa was -0.18, (95% CI: -0.72, 0.36). The pooled SMD of APTT among DM patients in Africa was -0.48, (95% CI: -1.18, 0.21). There was no statistically significant difference in the SMD of PT and APTT among DM patients in Africa compared to healthy controls. The pooled SMD of APTT among Type 1 DM patients in Africa was 0.86 (95% CI: 0.04, 1.69) whereas the SMD among Type 2 DM was -0.42 (95% CI: -1.24, 0.40). The SMD of APTT in Type 1 DM and controls showed a statistically significant difference compared with Type 2 DM and controls (p = 0.041). The SMD of APTT in Africa that is determined using a case-control study design showed a statistically significant difference compared to the SMD that is determined using a comparative cross-sectional study design.

Conclusion and recommendations: Even though different studies conducted across African countries showed the presence of coagulation abnormality in DM, this systematic review and meta-analysis revealed that there is no statistically significant SMD of PT and APTT in DM patients compared to healthy controls. However it is recommended that physicians routinely check APTT levels in Type I DM patients in order to evaluate coagulation status.

Keywords: Africa; activated partial thromboplastin time; diabetes mellitus; prothrombin time; systematic review and meta-analysis.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Flow chart of the selection of studies for the systematic review and meta-analysis on the evaluation of prothrombin time and activated partial thromboplastin time among diabetic and healthy controls in Africa.
Figure 2
Figure 2
The pooled SMD of PT among diabetes patients in Africa. SMD, Standard Mean Difference; I-square, heterogeneity statistic.
Figure 3
Figure 3
The pooled SMD of PT among diabetes patients in Africa based on the type of diabetes. SMD, Standard Mean Difference; I-square, heterogeneity statistic.
Figure 4
Figure 4
The pooled SMD of PT among diabetes patients in Africa based on region. SMD, Standard Mean Difference; I-square, heterogeneity statistic.
Figure 5
Figure 5
The pooled SMD of PT among diabetes patients in Africa based on study design. SMD, Standard Mean Difference; I-square, heterogeneity statistic.
Figure 6
Figure 6
Funnel plot of the included studies to determine the pooled SMD of PT among diabetes patients in Africa.
Figure 7
Figure 7
Forest plot of the included studies to determine the pooled SMD of PT among diabetes patients in Africa.
Figure 8
Figure 8
The pooled SMD of APTT among diabetes patients in Africa. SMD, Standard Mean Difference; I-square, heterogeneity statistic.
Figure 9
Figure 9
The pooled SMD of APTT among diabetes patients in Africa based on the type of diabetes. SMD, Standard Mean Difference; I-square, heterogeneity statistic.
Figure 10
Figure 10
The pooled SMD of APTT among diabetes patients in Africa based on region. SMD, Standard Mean Difference; I-square, heterogeneity statistic.
Figure 11
Figure 11
The pooled SMD of APTT among diabetes patients in Africa based on study design. SMD, Standard Mean Difference; I-square, heterogeneity statistic.
Figure 12
Figure 12
Funnel plot of the included studies to determine the pooled SMD of APTT among diabetes patients in Africa.
Figure 13
Figure 13
Forest plot of the included studies to determine the pooled SMD of APTT among diabetes patients in Africa.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, et al. . On behalf of the American diabetes, association 2. Classification and diagnosis of diabetes: standards of Care in Diabetes-2023. Diabetes Care. (2023) 46:S19–s40. doi: 10.2337/dc23-S002, PMID: - DOI - PMC - PubMed
    1. Leslie RD, Palmer J, Schloot NC, Lernmark A. Diabetes at the crossroads: relevance of disease classification to pathophysiology and treatment. Diabetologia. (2016) 59:13–20. doi: 10.1007/s00125-015-3789-z, PMID: - DOI - PubMed
    1. Sun H, Saeedi P, Karuranga S, Pinkepank M, Ogurtsova K, Duncan BB, et al. . IDF diabetes Atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. (2022) 183:109119. doi: 10.1016/j.diabres.2021.109119, PMID: - DOI - PMC - PubMed
    1. Atlas D. IDF diabetes atlas. 9th ed. Available at: http://www.idf.org/about-diabetes/facts-figures International Diabetes Federation; (2019).
    1. Atlas D. International diabetes federation. IDF Diabetes Atlas. 7th ed. International Diabetes Federation: Belgium; (2015).

Publication types

LinkOut - more resources